We are thrilled to announce that Alan Harris has joined Bespak as our new Chief Technical Officer (CTO)! Alan brings over 25 years of experience in respiratory product development and manufacturing, making him a fantastic addition to our leadership team. Alan will drive Bespak’s product development and technology strategy, leading our research and development team in the low GWP pMDI transition, and driving innovation, sustainability and agility into our projects. His expertise in branded and generic inhaled product development will be pivotal as we continue to advance our product and service offerings, shaping the future of inhaled drug delivery solutions in partnership with our customers. Chris Hirst CEO, said: “As the specialist inhalation CDMO, we are 100% focused on inhaled drug delivery – and Alan’s experience developing and commercialising branded and generic respiratory products adds further weight to our world-class R&D credentials. We are excited for what we can achieve at Bespak, and what we can deliver for our customers, with Alan’s technical leadership.” Welcome to Bespak, Alan! #Bespak #Sustainability #InhalationDevices #pMDI #ClimatefriendlyPropellants #DrugDelivery #CDMO
Bespak
Pharmaceutical Manufacturing
Holmes Chapel, England 8,274 followers
Bespak is a global contract development and manufacturing organisation (CDMO) focused on inhaled and nasal drug delivery
About us
Bespak is a global contract development and manufacturing organisation (CDMO) focused on inhaled and nasal drug delivery devices and drug-device combination products. Bespak develops and manufactures finished pharmaceutical products, as well as being a leading global supplier of drug delivery devices and componentry to the pharmaceutical industry. With a long history in the development and commercial supply of pressurised Metered Dose Inhalers (pMDIs), Bespak supplies a major proportion of the world’s pMDI dosing valves and actuators, and also specialises in the industrialisation and high-volume manufacture of complex dry powder inhaler (DPI) devices. Headquartered in Holmes Chapel, UK, the company’s service offering spans early-stage feasibility, analytical and product development, through pilot-scale, clinical and commercial-scale drug product fill-finish, to device and component manufacturing.
- Website
-
bespak.com
External link for Bespak
- Industry
- Pharmaceutical Manufacturing
- Company size
- 1,001-5,000 employees
- Headquarters
- Holmes Chapel, England
- Type
- Privately Held
- Founded
- 1959
- Specialties
- Inhaled & Nasal Drug Delivery, pressurised Metered Dose Inhalers, pMDI Valves & Actuators, Dose Counters, Formulation & Product Development, Pilot-scale, Clinical & Commercial-scale Manufacturing, Low GWP Propellants, Drug Delivery Devices, Plastic Injection Moulding, Pulmonary, Nasal, CDMO, and Innovation & Sustainability
Locations
-
Primary
London Road
Holmes Chapel, England CW4 8AY, GB
-
Bergen Way
Kings Lynn, Norfolk PE30 2JJ, GB
-
511 Davis Dr
Morrisville, North Carolina 27560, US
Employees at Bespak
-
Louise Righton
-
Anne Whitaker
Independent Director | Private Equity and Board Advisor l Board of Directors Chairwoman l Experienced Biotech CEO and Large Pharma C-Suite Leader
-
Francois Billard
-
Kevin Clancy, MBA
Finance Director | Business Partner | Division & Business Unit Finance Leader - Driven to Improve Results through Expertise in Forecasting, Planning,…
Updates
-
We are excited to be attending RDD Asia next week, taking place in Kerala, India, November 19-21. We look forward to the workshops, posters and many discussions on how the industry is transitioning pMDIs to low GWP propellants. If you are attending, reach out to Richard Turner, Simon Gardner, Rudramurthy Prabhu, Chris Hirst or visit us at table 10, to hear more about how we can support low GWP pMDI development programmes and clinical trials using HFA-152a & HFO-1234ze. We can’t wait to see you there. https://lnkd.in/e_dYgv_3 #RDDAsia #Pharmaevent #Sustainability #Pharma #InhalationDevices #pMDI #ClimatefriendlyPropellants #DrugDelivery #CDMO
-
As #COP29 kicks off, we want to reflect on our achievements in sustainability at Bespak and share why this journey matters to us all. We’re making meaningful strides to reduce our carbon footprint, improve our sustainability practices and innovate responsibly, both for our business and for the world around us. We have already made significant efforts in reducing carbon emissions and considering our impact on sustainability. So far, we have: 👉Donated office furniture and equipment to the Remo and Lifeline Fund charities with Collecteco's assistance, resulting in an 8,193 kg waste reduction and 26.9 tCO2e avoidance. 👉 Installed electric car chargers at (12 chargers) Holmes Chapel and (4 chargers) at King’s Lynn sites for our staff members and visitors. 👉 Installed 2000 solar panels at Holmes Chapel site with a 227 tCO₂e saving in 2023 alone. 👉 Installed LED lighting across the whole business in our buildings and manufacturing areas saving 531 tCO₂e. 👉 Removed old HEPA filters, bag filters, and pre cotton filters for clean room HVAC units, and replaced with Camfill high energy efficient equivalent filters saving 494 tCO₂e. Alongside our existing efforts, we are proud to announce our new initiatives in exclusive partnership with Tunley Environmental. These include Life Cycle Assessments (LCAs) across our product range (including a Circular Economy Assessment), a Supply Chain Biodiversity Assessment, Sustainability trainings and Supply Chain Engagement. These initiatives will provide us with a comprehensive view of the carbon impact of our entire product range, enabling us to validate the low-carbon potential of each product. Additionally, they allow us to better understand our influence on biodiversity and address key areas in our supply chain to reduce Scope 3 emissions. Looking ahead, our initiatives will continue to focus on key sustainability improvements, including increasing Solar PV Capacity at our King's Lynn site, compressed air reduction in our manufacturing lines, and enhancing HVAC Filtration in our buildings. These initiatives reflect Bespak's commitment to sustainable operations, directly supporting our broader efforts to mitigate climate change. Read more: https://lnkd.in/e5VJExcj #COP29Azerbaijan #Bespak #Sustainability #Pharma #CDMO
-
Our collaboration with Orbia Fluor & Energy Materials (Koura) aims to speed the commercialisation of low global warming potential pMDIs utilising Orbia Fluor & Energy Materials’ Zephex® 152a propellant at our Holmes Chapel site. This collaboration further solidifies our commitment to the pMDI industry’s transition to more sustainable solutions. Following significant investments, we can now provide development services up to market approval for all pMDI formulations and propellants, supported by capacity for commercial supply. Read more here: https://lnkd.in/dQJw_RJS #Bespak #Sustainability #Pharma #InhalationDevices #pMDI #ClimatefriendlyPropellants #DrugDelivery #CDMO
-
Ready to face the changing #inhaled and #nasal #drugdelivery industry? With a growing biologics market and an evolving regulatory landscape, modern-day inhaled and nasal drug product development is a balancing act. Against this changing backdrop, CDMOs with specialist knowledge and expertise have a crucial role to play in helping pharma companies chart the best route forward. In the latest issue of PMPS, our experts show you what best practices look like in drug-device development, as well as what you should look for in a CDMO partner. Read the article to explore our team’s insights: https://lnkd.in/eTb6Sx6i #Bespak #Sustainability #Pharma #InhalationDevices #pMDI #ClimatefriendlyPropellants #DrugDelivery #CDMO
-
Ready to explore new horizons in greener inhaled and nasal drug delivery? From increasing global incidence of #respiratorydisease to rising greenhouse gas emissions, the pharma industry must consider how to produce much-needed medicines whilst minimising environmental impact. In the latest issue of ONdrugDelivery, Louise Righton, our Head of Strategic Marketing, and AB. Bakpa, Head of ESG, discuss the many aspects involved in driving #sustainability in #inhaleddrugdelivery – and the next steps going forward. For the full article visit: https://lnkd.in/eMyfykw5 #Bespak #Sustainability #Pharma #InhalationDevices #pMDI #ClimatefriendlyPropellants #DrugDelivery #LowGWP #ESG
-
Bespak’s Louise Righton was recently invited by Steve Augustyn of Cambridge Design Partnership to share her perspectives on the results of a recent survey into the future evolution of respiratory drug delivery. Along with Chris Hall of Shallcross Partners, Louise discusses current trends and future directions in inhalation, including the low GWP transition, usability improvements, and connectivity. Read more here: https://lnkd.in/eY-UNpDT #bespak #resyca #inhalation #cdmo #pMDI #lowGWP #SMI #respiratory #drugdelivery #sustainability #innovation #connectivity #devicedesign #inhalerdesign #pharma
A few weeks ago I shared a LinkedIn survey, following an interesting roundtable discussion with European Pharmaceutical Aerosol Group looking at trends in respiratory medicine. The, extremely informal, survey results provided an interesting snapshot of what is happening in respiratory medicine. In the article linked below, I discussed the survey results with Chris Hall of Shallcross Partners Ltd and Louise Righton of Bespak. Chris and Louise provided some fascinating insights to the survey results from the heart of the respiratory industry. If you work in respiratory drug delivery, I'd love to hear your thoughts. #Respiratory #DrugDelivery #Sustainability #GWP
-
Exciting news from DevPro Biopharma on its partnership with Honeywell to develop a low-emission albuterol inhaler! We are proud to be working with DevPro and Honeywell on this vital step in the #GreenTransition. Utilising the Honeywell Solstice Air HFO-1234ze propellant, the new inhaler will reduce carbon emissions by 99.9% compared to conventional #pMDIs, without compromising inhaler efficacy. Learn more here: https://lnkd.in/e4JJNsYy #Bespak #DevProBiopharma #Honeywell #pMDI #albuterol #inhalationdevices #greenpropellants #lowGWP #sustainability #drugdelivery
📰 NEWS RELEASE DevPro Biopharma is excited to announce that Honeywell technology will power our new groundbreaking low-emission albuterol inhaler. By using Honeywell Solstice Air technology, a low global warming potential (GWP) propellant, our new pMDI will reduce carbon emissions by 99.9% compared to conventional inhalers without compromising inhaler efficacy, enabling patients to manage their respiratory conditions while also contributing to reduced carbon emissions. ➡️ FULL RELEASE: https://lnkd.in/d_FmZx7 #DevProBiopharma #Respiratorycare #Innovation #Technology #Treatment #ClinicalTrials #RespiratorySolutions #asthma #development #environment #developmentaccelerator #clinicalresearch #clinicaldevelopment #pMDI #GoTeamDevPro #science #biopharma #patientsfirst #COPD
-
What an incredible time at CPHI! A huge thanks to everyone who stopped by the #Bespak booth, connected with us, and shared valuable discussions. See you in Frankfurt! #Bespak #industryleaders #CPHI2024 #BespakinMilan #pMDI #inhalationdevices #greenpropellants #sustainability #drugdelivery
-
It’s the final day here at #CPHI in Milan. We’ve had amazing conversations and are showcasing some exciting developments. Come visit us at booth 20B33 before the event ends! #Bespak #industryleaders #CPHI2024 #BespakinMilan #pMDI #inhalationdevices #greenpropellants #sustainability #drugdelivery